UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
Date of report (Date of earliest event reported)
|
|
|
|
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
||
|
(State of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(
|
|
(Registrant’s Telephone Number, Including Area Code)
|
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
|
Emerging growth company
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
|
☐
|
Item 7.01 Regulation FD Disclosure.
On January 11, 2022, Surmodics, Inc. (“Surmodics”) will post to its website at www.surmodics.com the investor information attached
to this report as Exhibit 99.1.
The information in this Item 7.01, including Exhibit 99.1 and the information accessed by links through QR codes appearing in
Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under Section 18, nor shall such information be deemed
incorporated by reference into any filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
Description
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
SURMODICS, INC.
|
|
|
|
|
|
|
|
|
|
|
Date: January 11, 2022
|
/s/Timothy J. Arens
|
|
|
|
Timothy J. Arens
|
|
|
|
Senior Vice President of Finance and Chief Financial Officer
|
|
Exhibit 99.1
January 2022 Gary MaharajPresident and CEOTim ArensSenior Vice President of Finance, IT and CFO 1 ©
2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Some of the statements made during this presentation may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements about growth opportunities, expected revenue growth and annual growth rates, our fiscal 2022
strategic objectives, statements about the commercialization potential of the SurVeil™ drug coated balloon (“DCB”), statements about the premarket approval and commercial launch of the SurVeil DCB, the expected timing of market evaluations of
our products, statements about future potential revenue from our Development and Commercialization Agreement with Abbott Vascular, Inc., expectations regarding completion of the 5-year follow-up in the TRANSCEND study, fiscal 2022 financial
guidance, and estimates of future revenues related to the TRANSCEND study, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ
materially from those anticipated, including (1) our ability to successfully develop and commercialize our SurVeil™ DCB (including realization of the full potential benefits of our agreement with Abbott), Avess™ DCB, Sundance™ DCB and other
proprietary products; (2) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies; (3) possible
adverse market conditions and possible adverse impacts on our cash flows; (4) the impacts, duration and severity of the global COVID-19 pandemic and the effects of responses to it on healthcare systems, the general economy, our business
partners, and our operations; (5) whether anticipated increases in our operating expenses are effective in generating profitable revenues; and (6) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K
for the fiscal year ended September 30, 2021, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov.
Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events. 2 Safe Harbor CAUTION: SurVeil™, Sundance™ and Avess™ Drug-Coated Balloons are
investigational devices. Limited by Federal (or United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
We Are On A Mission Simply Better. Because technology innovation is only as good as the confidence and
adoption of its users. We believe simpler and better is the way to go to enable greater access to care by giving physicians the freedom to treat, anytime, anywhere. Simply Better. 3 © 2022 Surmodics, Inc. CONFIDENTIAL All rights
reserved. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Simply Surmodics. Growth Opportunity: High-growth, underpenetrated market opportunities serving
current trends and future market needsCore Business: Strong source of operating cash fuels growth initiatives and commercial operationsStrong and growing businessesHigh ROIC Who are we? Learn more about us. Stopping Solutions & Support
ReagentsProtein Stabilizers & ELISA SubstratesAntigens & Antibodies (Diarect™)Microarray Slides & Surfaces In Vitro Diagnostics (IVD) Sublime™ Radial Access PlatformPounce™ Arterial ThrombectomyPounce™ Venous
ThrombectomyDrug-Coated Balloons Vascular Device Platforms Hemocompatible CoatingsDrug-Delivery CoatingsHydrophilic CoatingsCombination Coatings Performance Coatings 4 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. DIARECT is a
trademark of BBI Solutions and/or its affiliates. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Our Sights Are On Something Bigger 5 Driven to do More Global Leader Secret Sauce Born to
Innovate We Can Help The problems we address and the markets we serve are growing. We are directly relevant. The global leader in medical device coatings and in vitro diagnostics specialty reagents. We’ve been the secret sauce but received
a fraction of the value – and couldn’t control our destiny. We are innovators. We owe it to our shareholders to command the return that fully reflects the value of our innovations. Vascular disease is pushing healthcare to the brink. We can
make a difference. Our journey has prepared us. This is just the beginning. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply
Driven Simply Surmodics
What Matters Most PatientsNo one should suffer from lifelong disability when the right treatment at
the right time could have prevented it. CustomersLife-changing technology must move quickly into the hands of physicians everywhere. And it needs to happen fast.EmployeesSurmodics employees are personally invested to drive this change. That’s
why we work here.ShareholdersWe recognize the investment made to support our mission. We are driven to quickly maximize shareholder return. It’s personal.We are on a mission. 6 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply
Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
7 RADIAL ACCESS Simply Better Solutions DRUG-COATED BALLOONS We Innovate Learn more about
our product portfolios Vascular Device Platforms THROMB0-EMBOLECTOMY CAUTION: SurVeil™, Sundance™ and Avess™ Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. © 2022
Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
DIFFERENT It’s Not Enough To Be Different DIFFERENCE First 5F radial sheathLongest length balloon
cathetersBroke the trade-off between length & performance Stand-alone arterial mechanical device designed to clear chronic thrombo-embolic obstructionsGrab and go, on-table resolution First dual-action technologyGrab and go, on-table
resolutionDevice and procedure simplicity You can’t treat what you can’t reach. Get wherever you need to go — quickly and confidently – from any access site An arterial clot can quickly cost a limb – or a life. Strike fast with a simple,
surefire device that captures and removes hard clots Clots adhere to veins and damage them on contact. We believe in moving fast: just grab and go. First worldwide head-to-head RCT of next generation low-dose DCB vs high-dose DCB Comparable
effectiveness achieved at a substantially lower dose of drug 8 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to
investigational use. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Big Opportunities: We are Driven to Achieve PADPeripheral Artery Disease 0.8 M patients/year $0.4
BTAM <10%Penetrated PAO/DVTPeripheral Arterial Occlusion and Venous Thrombo-embolism 0.4 M patients/year $2.2 BTAM Market ~15%Penetrated PAD ATKPeripheral Artery Disease Above-the-knee 0.5 M patients/year $1.0 BTAM
Market ~20%Penetrated Large, Underpenetrated Markets Addressable By Our Innovations Patient figures and ASP ranges based on Management Estimates as well as Public Health and Industry Data © 2022 Surmodics, Inc. CONFIDENTIAL All rights
reserved. 9 Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Our Commercialization Strategies Enable Us To Maximize Our Opportunities In Significant And Growing
Markets Direct Commercial ValidationFocused commitment from sales and marketingProduct development initiatives to expand portfolioAbility to expand and grow marketsEnhanced customer insights to inform product development
initiativesDevelopment/Mfg. PartnershipSurVeil™ Drug-Coated Balloon Telemark™ MicrocatheterCook Advance Serenity™ PTA Balloons B2B Technology EnablerMedical Coatings and IVD VALUE CREATION POTENTIAL RELEVANCE Direct
Commercial Validation 100%of ASP Development/Manufacturing Partner % of ASP Technology Enabler % of ASP 10 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. For illustration only. No representation is made or implied
regarding the actual revenue Surmodics realizes relative to the ASP of any medical device or product. CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational
use. ADVANCE SERENITY is a trademark of Cook Medical Technologies LLC and/or its affiliates. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Innovative product pipeline aimed at significant growth opportunitiesSeeking FDA approval for SurVeil™
DCB, which will address a $1.5B worldwide market opportunity through our commercial partner, Abbott(1)U.S. FDA clearances on five unique and differentiated thrombectomy and radial access products to address market opportunities totaling up to
$2.6 billion (1)Direct commercialization of our thrombectomy and radial access products in FY2022Current team of 12 experienced sales professionals (avg. experience 21 years)will build on success with initial clinical
evaluationsTechnology-enabling Medical Device Coatings and In Vitro Diagnostics offerings Generate $80+ million of revenue annuallyExpected to grow annually in the mid single digits Provide consistent and reliable cash flow 11 We Are
Committed To Driving Long-term Revenue Growth And Value Creation For Our Shareholders (1) Patient figures based on Management Estimates as well as Public Health and Industry Data CAUTION: SurVeil™ Drug-Coated Balloon is an investigational
device. Limited by Federal (or United States) law to investigational use.(1) Patient figures based on Management Estimates as well as Public Health and Industry Data © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply
Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
12 Our Fiscal 2022 Objectives Support Our Mission. SurVeil™ Drug-Coated BalloonAchieve FDA PMA
ApprovalSupport the commercialization efforts of our partner, Abbott VascularPounce™ Thrombectomy Platform and Sublime™ Radial Access platformsValidate commercial opportunityCapitalize on physician preference by establishing solid customer base
with repeat businessMedical Device Coatings and In Vitro Diagnostics offerings Drive top-line revenue growth and optimize cash flow 1 2 3 CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or
United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
13 CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United
States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
GOALS for 3rd generation device are focused on addressing important clinical problemsCLINICAL – Similar
therapeutic outcome with lower doseLower potential for complications Wider therapeutic windowTECHNOLOGICAL – Reduce Paclitaxel dose to 2.0 µg/mm²; improve uniformity of drug delivery/distributionBetter efficiency of drug transferReduction in
downstream embolizationMarket-leading device has 75% higher dose SurVeil™ DCB: Third-Generation Design THESIS: similar outcome with lower dose of cytotoxic drug Advance the state of the art Provide better therapeutic choice SurVeil™
DCB Check here for product specs and TRANSCEND 12-month data 14 CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL
All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States)
law to investigational use. Commercialization Of Our SurVeil™ DCB Has The Potential To Be A Significant Growth Catalyst 15 ~100,000 Above-the-knee Balloon Angioplasty Market – U.S.(1) Annual SFA Procedures in the US Annual ATK DCB
Procedures in the US ~500,000 (1) Patient figures based on Management Estimates as well as Public Health and Industry Data TRANSCEND 12-mo. data presented at Leipzig Interventional Course (LINC) 2021 All modules for FDA PMA approval have
been submitted Jan 2021 Jun 2021 FY22/FY23 Targeting PMA approval and commercial launch with our partner, Abbott Jun 2020 CE markreceived Our commercial partnership with Abbott is expected to lead to a significant and
growing revenue stream upon commercialization © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
DCB Platform Extensions Avess™ AV Fistula DCB Sundance™ Below-The-Knee DCB First in human study
results presented at 2020 VIVA conference by Dr. Andrew Holden, MBChBFreedom from revascularization at six months was greater than 90% for the 12 subjects (one re-intervention) with no AVF’s thrombosed. Safety endpoints met. First in human
study 6-month follow-ups complete and preliminary analysis underway Surmodics .035” PTA platform4 – 12 mm diameter40 – 80 mm lengths Uniform paclitaxel drug coatingPaclitaxel + Proprietary Excipient360° uniform coating coverage Surmodics
.014” PTA platform2 – 4 mm diameter20 – 220 mm lengths Uniform sirolimus drug coatingSirolimus + Proprietary Excipient360° uniform coating coverage Hydrophilic shaft coatingSurmodics Serene™ hydrophilic coating 16 CAUTION: Sundance™ and
Avess™ Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply
Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Poised, Positioned and Ready to Pounce 17 Poised: Two stand-alone, easy-to-use, highly effective
mechanical thrombectomy devices; one for arterial use, the other for venous casesPositioned: Simple, effective designs make these devices ideal first-line treatments in their respective spacesPounce into action with intuitive, off-the-shelf
devices that empowers physicians to rapidly respond, remove clot, and restore blood flow when time is of the essence Poised, Positioned and Ready to Pounce. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply
Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
18 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
An Elegant Solution to a Complex Clinical Problem 19 Pounce™ Arterial Thrombo-embolectomy
SystemDesigned to capture and remove organized and unorganized thrombo-emboli in the arterial peripheral vasculatureOff-the-shelf, stand-alone device – designed for use in time critical situations, with no additional capital equipment required.
Packaged in one ‘grab & go’ configuration.Intuitive, simple set up, limited learning curveOn-the-table solution designed to lower risk of bleeding complications associated with use of thrombolytics Check out the full animation and
additional product details After the basket wire assembly is delivered distal to the location of the thrombus, two nitinol self-expanding baskets are deployed distal to the clot. The baskets capture the clot and are retracted into a
trumpet-shaped nitinol wire mesh. With the clot entrained, the trumpet assembly is then collapsed into a minimum 7 Fr guide sheath through which the clot is withdrawn and removed from the body. © 2022 Surmodics, Inc.
CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Iliofemoral DVT patients Patients treated with mechanical thrombectomy 240,000 21,000 There Are
Large, UnderpenetratedMarket Opportunities In Clot Removal 20 ARTERIAL CLOT REMOVAL U.S. MARKET Arterial$0.8 Billion30% Current PenetrationASP Ranges: $2K – $5K Patient figures and ASP ranges based on Management Estimates as well as Public
Health and Industry DataOur devices have not received DVT and/or PE disease state clinical indication clearance at this time. PAO/CLI patients Patients treated with arterial clot removal procedure 185,000 55,000 Massive and Sub-Massive
PE’s Patients treated with mechanical thrombectomy 200,000 15,000 VENOUS THROMBOEMBOLISM (VTE) CLOT REMOVAL U.S. MARKET DVT$1.4 Billion9% Current PenetrationASP Ranges: $2K – $7K PE$1.7 Billion8% Current PenetrationASP Ranges: $2K –
$12K © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
21 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
DVT is a major health problem affecting >800,000 U.S. patients/year(1)Currently available technologies
have shortcomings that limit broad-scale adoptionDelays in treatment can impact longer-term outcomes and elevate risk of post-thrombotic syndrome There’s a Lot More Life Left in These Limbs Clinical Indication: Indicated for mechanical
de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature Get In. Get Out. Get on With Life. Device Status:FDA Clearance 2020; CE Mark approval 202119-patient study
with 12-month follow-upMarket evaluations scheduled 2022 (1) Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596. 22 ©
2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Pounce Venous Thrombectomy: Patient First Because a vein is an organ. Self-adapting radial force:
Basket maintains consistent circumferential force in veins ranging from 6-16 mm diameter Minimal hardware footprint: Rounded outer edge of the flexible basket is the only point where metal meets tissue Reduced landing zone: Pounce venous
thrombectomy requires a shorter landing zone compared to the longer coring mechanism and collection bag of competitive mechanical device Competitive Device Pounce™ Venous Thrombectomy Iliofemoral clot Atraumatic design. 10 Fr
access: Lower profile reduces concerns about popliteal access, anatomical impact, and closure complications. Designed to separate, not core. Venous thrombectomy should strive to be faster, more efficient, more intuitive and minimize hardware
impact on anatomy The goal: Enable faster treatment and greater accessibility throughout the healthcare system 10 Fr Diameter Range6 – 16 mm Compatible Guidewire.018” OTW 23 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply
Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Pounce Venous Thrombectomy: Product Design Expand the basket using the handle dial. Activate the
extraction screw Pull the catheter through the clot Dual-action Mechanical Thrombectomy separates clot from vein wall and extracts it at the point of collection—without removing the device from the patient Wall-to-wall clot captureConsistent
spring tension basket separates clot from the vein wall and channels it to a window on the catheter lumen Motorized removalThe 25,000-RPM extraction screw draws clot from the basket and rapidly removes it from the patient See it in
action. View the animation and device specs 24 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
25 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Peripheral Vascular Interventions (PVIs) are rapidly shifting to office-based
labs HOSPITAL(25.7%)Decrease in PVI ASC(12.9%)Decrease in PVI OBL305.7%Increase in PVI PVI SERVICES BY LOCATION Targeting the Greatest Needs and Largest Opportunities Majority of PVI procedure growth is focused below the knee
(BTK) FEMOROPOPLITEAL 28.5% ILIAC (18%) TIBIAL/PERONEAL74% CHANGE IN PVI PROCEDURE VOLUME BY ANATOMICAL LOCATION 31.3%Increase in PVI Schramm KM, DeWitt PE, Dybul S, et al. Recent Trends in Clinical Setting and Provider Specialty
for Endovascular Peripheral Artery Disease Interventions for the Medicare Population. J Vasc Interv Radiol. 2020;31(4):614-621.e2. Perfect for the OBL: Radial is less invasive, fewer complications, rapid recovery, faster throughput When a
limb is on the line, you absolutely, positively have to get there (from any access site). 26 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply
DCB Simply Driven Simply Surmodics
1. As compared to transfemoral access in coronary procedures 2. Jolly SS, Yusuf S, Cairns J, et al.
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377:1409-20. 3. Ferrante G, et al. Radial Versus Femoral
Access for Coronary Interventions Across the Entire Spectrum of Patients with Coronary Artery Disease. A Meta-Analysis of Randomized Trials. JACC: Cardiovascular Interv. Vol 9(14),25 July 2016:1419-1434. 4. Lindner SM, McNeely CA, Amin AP. The
Value of Transradial: Impact on Patient Satisfaction and Health Care Economics. Interv Cardiol Clin. 2020 Jan;9(1):107-115. 5. Cooper C, El-Shiekh R, Cohen D, et al. Effect of transradial access on quality of life and cost of cardiac
catheterization: a randomized comparison. Am Heart J. 2010; 138(3), 430-436. Radial Access Technology Can Accelerate the Shift to OBLs © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Learn more about the proven benefits of radial
access Lasting impressions last. REDUCED BLEEDING47% reduction in major bleeding and a 77% reduction in complications when using radial access1,3 POSITIVE EXPERIENCEPatients prefer transradial approach because they experienced less pain
and greater walking ability post-procedure1,5 REDUCED COMPLICATIONS50–80% relative risk reduction in access site complication1,2 RAPID RECOVERYQuick ambulation and early discharge frees up staff, beds and resources to increase
volume1,4 27 Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Sublime™ Radial Access Expands The Market By Enabling Radial Access Radial Access PTA Catheter U.S.
Market Patient figures and ASP ranges based on Management Estimates as well as Public Health and Industry Data Patients treated with 018” PTA interventions 0.018” PTA (ATK+BTK)$50 Million8% Current Penetration Patients treated with 014” PTA
interventions 0.014” PTA (BTK)$60 Million<1% Current Penetration Radial Guide Sheath$240 Million9% Current Penetration 125,000 150,000 13,000 <1,000 Patients treated with radial access interventions Patients treated with radial
access interventions Radial Access Guide Sheath U.S. Market 70,000 Patients treated with radial access interventions Patients treated with ATK or BTK Interventions 810,000 28 © 2022 Surmodics, Inc. CONFIDENTIAL All rights
reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Sublime™ Platform Can Get You There From Any Access Site When a limb is on the line, physicians need to
be confident they can tackle tough lesions. Why will SUBLIME products make you jump for joy? Sublime™ Guide Sheath beats the competition:Kink resistance – 60% better kink resistance1Radial Strength – 15% stronger1Torque Transmission –
1.3X better torque response1Sublime™ PTA Balloons provide superior lesion crossing capabilities at longer lengths than othersCrossability1 and pushability1 exceed other PTA balloonsOur 250 cm 014” Sublime™ RX PTA catheter is 50 cm (25%) longer
than any other commercial 014” PTA balloon When It Absolutely, Positively Has To Get There. 1Based on average measurements from bench testing by Surmodics, Inc. Data on file. Scan QR code to view competitive testing. 29 © 2022 Surmodics,
Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Medical Device Coatings 30 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
The Magic Is In The Coating CardiovascularRoyalty Rev = 25-35%CAGR = (1)-2% NeurologicalRoyalty Rev =
25-35%CAGR = 6-10% Peripheral VascularRoyalty Rev = 25-35%CAGR = 4-6% Structural HeartRoyalty Rev = <10%CAGR = 12–15% 25%-35% <10% ROYALTY REVENUE DISTRIBUTION1 Estimated Distribution of Surmodics’ Royalty Revenues 1 CAGRs =
Needham & Associates and Company estimates (prior to COVID-19 Pandemic)2 Based upon Surmodics’ historical royalty revenue mix Hydrophilic Low friction and low particulates to improve deliverability Drug-Delivery Durable and
biodegradable coatings using proprietary polymers to control delivery rates and mechanical properties Hemocompatible Active and passive coatings; customizable to blood compatibility and durability requirements Surmodics’ coatings are
critical to the successful delivery of medical devices used in complex procedures where maneuverability and control are essential See why we’re the best Watch video 31 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply
Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
(1) Medical Device Coatings Over 150 license agreements among 100 customers30 U.S. patents issued; 64
International patents IssuedRoyalty rates for new licenses typically range from 2-3% for the device applicationProduct gross margins on the high end of medical device industry averages A Stable Foundation For Future Growth 32 Growth: 4%
(10)% 10% (1) Impacted by COVID-19 as well as patent expiration for our 4th generation coating REVENUE BREAKDOWN © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply
Pounce Simply DCB Simply Driven Simply Surmodics
33 In Vitro Diagnostics (IVD) © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Leading Provider Of Components for IVD Tests and Microassays In Vitro DiagnosticsOur components are used
in test kits sold by the majority of the top ten global in vitro diagnostics companies> 1000 unique customers in several categories: Kit manufacturers, R&D institutions, Distributors and OEM’sPoint of care testing and regulatory changes
are disrupting the market and represent opportunity for market share growth Protein stabilizers, diluents & blockers ELISA substrates Microarray slides & surfaces Antigens & antibodies from DIARECT™ part of BBI solutions™ Stop
solutions & support reagents Check out our full lineof products 34 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply
Driven Simply Surmodics
Our Business Model Creates Long-lasting Partnerships Development PartnersPartnering with customers
during test development allows us to supply high performance critical raw material components for new immunoassay tests Focus on QualityOur focus on quality ensures streamlined manufacturing and consistent assay performance throughout the
commercial life of the product Customer ServiceGold standard customer service, technical support and regulatory expertise keep customers loyal to Surmodics IVD 35 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply
Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Continued Outstanding Results 36 IN VITRO DIAGNOSTICS Growth: 4% 8% 14% Our IVD business is expected
to continue to deliver mid-to-high single digit revenue growth annuallyStrong and growing customer base with broad portfolio of differentiated products Operating margin has improved each of the past three years to approximately 51% of revenue,
or $13.8 million in FY2021 The $15-$17B global immunoassay market is expected to grow 3-4%, annually Recent M&A transactions have valued diagnostics suppliers at 14-16X EBITDA(1) (1) Recent precedent transactions © 2022 Surmodics, Inc.
CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
37 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Surmodics Business Segments For the twelve
months ended September 30, 2021 BUSINESSSEGMENTREVENUE IVDBUSINESS26% MEDICAL DEVICES74%
QUARTERLY REVENUE (MILLIONS) (1) (1) Includes $10.8 million related to the successful completion of a
milestone in our SurVeil™ DCB agreement with Abbott ANNUAL REVENUE (MILLIONS) History of Strong Financial Performance 38 Funding our Growth Investments from Within: Our solid balance sheet and financial performance has self-funded our
growth-driving portfolio investments$40.9 million of cash/investments as of September 30, 2021Operating cash flow of $15.4 million and Adjusted EBITDA of $12.0 million for fiscal 2021 CAUTION: SurVeil™ Drug-Coated Balloon is an investigational
device. Limited by Federal (or United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply
Surmodics
Capital Allocation Priorities 39 Available Capital ($’s in Millions) September 30,
2021 Cash $31.2 Available-for-sale Investments $9.7 Revolving Line-of-Credit $15.0 Total $55.9 Available Capital Protect Liquidity & Balance Sheet Invest in Long-term Value Creation Our long-term capital allocation priorities
remain unchangedWe continue to support long-term value creation through investment in our innovative product platforms Support the Core BusinessesOptimize revenue and cash flow performance Validate Commercial OpportunityBuild infrastructure
to support commercialization of our Pounce™ and Sublime™ products Invest inInnovationDrug-coated balloonsThrombectomy platformRadial access platform © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply
Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply Surmodics
Financial Guidance(As presented Nov. 10, 2021) 40 2022 Financial Guidance Long Term Objectives Total
Revenue: $97 million to $101 million, including:$4.5 - $5.0 million of SurVeil™ DCB license fee revenue (compared with $16.0 million in fiscal 2021)(1) $2.0 - $2.5 million of Pounce™ and Sublime™ product sales GAAP Loss per Share(2): $(2.05) to
$(1.55), including:Approximately $10 million to support commercialization of our Pounce™ and Sublime™ productsApproximately $10 million of additional R&D investments to accelerate strategic initiativesNon-GAAP Loss per Share(2): $(1.75) to
$(1.25) Consistent double-digit revenue growth beginning in fiscal 2023, driven by expected commercialization of SurVeil™, Pounce™ and Sublime™ Our fiscal 2022 SurVeil DCB revenue is driven by the recognition of the upfront and milestone
payments totaling $61.8 million that have been received, pursuant to our distribution and development agreement with Abbott.GAAP earnings per share is the estimated fiscal 2022 diluted earnings per share as determined by U.S. generally accepted
accounting principles. Non-GAAP earnings per share adjusts GAAP earnings per share for estimated fiscal 2022 acquired intangible amortization totaling $0.30 per share, net of tax. CAUTION: SurVeil™ Drug-Coated Balloon is an investigational
device. Limited by Federal (or United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Simply Better. Simply Strong Simply Solid Simply Radial Simply Pounce Simply DCB Simply Driven Simply
Surmodics
41 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. SURMODICS, SUBLIME, POUNCE, SURVEIL,
SUNDANCE, AVESS, TELEMARK, SERENE and the SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE and AVESS logos are trademarks of Surmodics Inc. and/or its affiliatesAll rights reserved. 01/22
Appendix 42 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Strategic Agreement with Abbott February 27, 2018 – Abbott and Surmodics Announced Agreement for
Next-Generation Drug-Coated Balloon Development and CommercializationExclusive worldwide commercialization rights for SurVeil™ drug-coated balloon (DCB) for superficial femoral artery (SFA)Option to negotiate agreement for Sundance™
below-the-knee (BTK) DCBWe have received $60.8 million in total milestones from AbbottFinal milestone of up to $30 million due upon receipt of PMA approval from the FDAReceived Abbott’s good faith estimate of U.S. product launch
quantitiesRevenue to be realized from product sales to Abbott, including a base transfer price plus a share of profits from Abbott sales of the device 43 CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal
(or United States) law to investigational use.ABBOTT and ABBOTT logo are trademarks of Abbott Laboratories Corp. and/or its affiliates. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Based on the costs incurred and expected to be incurred from the execution of the Abbott agreement and
not the actual cost from study inceptionPMA milestone revenue would be approximately $25M if the milestone is met in fiscal 2022We expect to recognize the entire $60.8 million associated with the license fee and achieved milestones over the
period ending fiscal 2025; revenue from the $30 million of outstanding milestones (if any) will be recognized over the same time period, beginning in the period of achievement Surveil™ DCB - Impact to Financials TRANSCEND Study Cost
Schedule(1) Payment Amount Date Upfront License Fee $25M Feb 2018 TRANSCEND Enrollment Milestone $10M Aug 2019 CE Mark Milestone $10.8M June 2020 Clinical Report Milestone $15M Feb 2021 $61M of the potential $91M of SurVeil™
DCB upfront and milestone payments have been achieved through Q4 FY2021 Upfront and milestone revenue is recognized based upon the % of the TRANSCEND study costs incurred*For example, FY’19 revenue was recognized as follows:Upfront license
fee - $25M x (~51% - ~18%) = $8.4MTRANSCEND completion milestone - $10M x ~51% = $5.1M FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Value Creating Event TRANSCEND Enrollment Complete U.S. PMA Approval
Expected 5-year Follow-Up Complete Estimated % of TRANSCEND Study Costs Incurred * ~ 51% ~ 76% ~ 100% Revenue Recognition Schedule Revenue ($ in millions) FY 2019A FY 2020A FY 2021A FY 2022E Upfront License
Fee $8.4 $3.5 $2.6 $1.8 – $2.0 TRANSCEND Completion Milestone 5.1 1.4 1.0 0.7 – 0.8 CE Mark Milestone - 7.0 1.1 0.8 – 0.9 Clinical Report Milestone - - 11.3 1.2 – 1.3 PMA Approval Milestone (2) - - - - Total SurVeil
Upfront & Milestone Revenue $13.5 $12.0 $16.0 $4.5- $5.0 Cumulative Revenue $17.9 $29.9 $45.9 $50.4 - $50.9 % recognized * ~ 51% ~ 65% ~ 76% ~ 82-84% *TRANSCEND costs incurred following the execution of the SurVeil™ DCB
development and distribution agreement with Abbott Vascular ~78% of the estimated total $35M – $40M TRANSCEND Clinical Study costs were incurred through Q4 2021 CE Mark Received ~ 65% ~18% Abbott Agreement Signed ~ 83% Final Clinical
Report Delivered CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. 44 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
MANAGEMENT TEAM 45 Gary R. MaharajPresident and Chief Executive Officer (2010) Timothy J.
ArensSenior Vice President of Finance and Information Technology and Chief Financial Officer (2007) Joseph J. Stich Senior Vice President of Human Resources and General Manager of In Vitro Diagnostics (2010) Gordon S. WeberSenior Vice
President of Legal,General Counsel & Secretary (2020) Charles W. OlsonSenior Vice President of Commercial and Business Development, Medical Devices(2001) Teryl L.W. Sides Senior Vice President of Product Development and Chief Marketing
Officer, Vascular Interventions(2018) Nusrath Sultana, M.D.Vice President of Clinical Affairs (2020) IN VITRO DIAGNOSTICS VASCULAR INTERVENTIONS MEDICAL DEVICES © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. © 2022 Surmodics,
Inc. CONFIDENTIAL All rights reserved.
46 Clinical Advisors Ken Rosenfield, MD Chair Advisory Board — Interventional CardiologyMassachusetts
General Hospital Gary Ansel, MD, FACC Clinical Advisor — Interventional CardiologyHealthcare Insights Marianne Brodmann MD, PhD Clinical Advisor— Interventional CardiologyDivision of Angiology Medical University Graz Raghu Kolluri, MD, MS,
RVTClinical Advisor — Vascular Medicine & Vascular LabsOhio Health Heart and Vascular Service Renu Virmani, MD, FACCClinical Advisor — Cardiovascular PathologistCVPath Peter Schneider, MDClinical Advisor — Vascular SurgeryUniversity
California San Francisco Prof. Ramon VarcoeClinical Advisor — Vascular SurgeonPrince of Wales Hospital Constantino Peña, MDClinical Advisor — Vascular and Interventional RadiologyMiami Cardiac & Vascular Institute Michael Lichtenberg,
Clinical Advisor — Interventional AngiologistKlinikum Hochsauerland Stephen Black, MDClinical Advisor — Vascular SurgeonSt. Thomas Hospital © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. © 2022 Surmodics, Inc. CONFIDENTIAL All
rights reserved.